Classes
DEA Class; Rx
Common Brand Names; Kengreal
- Antiplatelet Agents, Cardiovascular
Description
Injectable P2Y12 platelet inhibitor indicated as an adjunct to PCI in patients not already receiving an oral P2Y12 inhibitor or glycoprotein IIb/IIIa inhibitor
Onset of platelet inhibitor occurs within 2 minutes of initiation of therapy and returns to normal within 1 hour of discontinuation
Contraindicated in patients with active significant bleeding
Indications
Indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor
Contraindications
Significant active bleeding
Hypersensitivity
Adverse Effects
GUSTO trial data
- Mild (14.9%)
- Moderate (0.4%)
- Severe/life-threatening (0.2%)
TIMI trial data
- Minor (0.6%)
- Major (0.2%)
Worsening renal function in patients with CrCl <30 mL/min (3.2%)
Hypersensitivity
Warnings
Drugs that inhibit platelet P2Y12 function, increase risk of bleeding
Increased risk of bleeding; bleeding events of all severities were more common with cangrelor than with clopidogrel
Bleeding complications were consistent across a variety of clinically important subgroups
Once therapy is discontinued, there is no antiplatelet effect after an hour
Pregnancy and Lactation
There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; untreated myocardial infarction can be fatal to pregnant women and fetus
There are no data on presence of drug in human milk or animal milk, effects on breastfed infant, or on milk production; due to its short-half life, drug exposure is expected to be very low in breastfed infant
Maximum Dosage
30 mcg/kg IV bolus; 4 mcg/kg/minute IV infusion.
30 mcg/kg IV bolus; 4 mcg/kg/minute IV infusion.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Not indicated.
Not indicated.
How supplied
Cangrelor
injection, lyophilized powder for reconstitution
- 50mg/vial
